



(43) International Publication Date
7 June 2012 (07.06.2012)

(10) International Publication Number
WO 2012/073146 A1

- (51) **International Patent Classification:**
C07D 215/58 (2006.01) *A61P 25/28* (2006.01)
A61K 31/4704 (2006.01)
- (21) **International Application Number:** PCT/IB2011/055190
- (22) **International Filing Date:**
18 November 2011 (18.11.2011)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/418,791 1 December 2010 (01.12.2010) US
61/419,232 2 December 2010 (02.12.2010) US
- (71) **Applicant (for all designated States except US):** **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **DOUNAY, Amy Beth** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340 (US). **HELAL, Christopher John** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340 (US). **TUTTLE, Jamison Bryce** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340 (US). **VERHOEST, Patrick Robert** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340 (US).
- (74) **Agent:** **BENSON, Gregg, C.**; Pfizer Inc., Eastern Point Road, MS 9114, Groton, CT 06340 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) **Title:** KAT II INHIBITORS

(57) **Abstract:** The present invention relates to compounds 3-amino-1-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline-7-carbonitrile, 3-amino-1-hydroxy-7-(2-methoxyethoxy)-3,4-dihydroquinolin-2(1H)-one, and 3-amino-1-hydroxy-7-[(1S)-2-methoxy-1-methylethoxy]-3,4-dihydroquinolin-2(1H)-one, including racemic mixtures and resolved enantiomers thereof, to pharmaceutically acceptable salts thereof, and to the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.



WO 2012/073146 A1